1 / 0

INVESTIGATION AND MANAGEMENT OF OBESITY

INVESTIGATION AND MANAGEMENT OF OBESITY. Dr Ogunwale O.O. MBBS Lagos Snr Registrar EDM Div. LUTH. OUTLINE. INTRODUCTION CLASSIFICATION AIMS OF INVESTIGATION INVESTIGATIONS TREATMENT GUIDELINES NON-PHARMACOLOGICAL MGT PHARMACOLOGICAL MGT SURGICAL MGT BENEFITS OF WEIGHT LOSS

chava
Télécharger la présentation

INVESTIGATION AND MANAGEMENT OF OBESITY

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. INVESTIGATION AND MANAGEMENT OF OBESITY

    Dr Ogunwale O.O. MBBS Lagos Snr Registrar EDM Div. LUTH
  2. OUTLINE INTRODUCTION CLASSIFICATION AIMS OF INVESTIGATION INVESTIGATIONS TREATMENT GUIDELINES NON-PHARMACOLOGICAL MGT PHARMACOLOGICAL MGT SURGICAL MGT BENEFITS OF WEIGHT LOSS COMPLICATIONS OF TREATMENT CONCLUSION REFERENCES
  3. INTRODUCTION Basically a clinical/anthropometric diagnosis History & PE vital. Underlying cause needs be investigated Classification based on BMI Also on Body Fat Distribution/% Not necessarily about ↑weight. but ↑body fat Mgmt. is multidisciplinary
  4. CLASSIFICATION BMI (Kg/m2) Body Fat Percentage (%)
  5. CLASSIFICATION Surgical : Super Obese BMI : ≥ 50 BF% : Calculated from Deurenberg’s Equation 1.2(BMI)+0.23(Age)-10.8(Sex)-5.4 Sex : 1 for Male, 0 for Female Both Underweight & Overweight are assoc. with ↑risk of dx. Risk ↑ with ↑ Obesity
  6. AIMS OF INVESTIGATION Confirm diagnosis & r/o differentials Find underlying aetiology Complications & Comorbidities
  7. INVESTIGATIONS BMI = Wt in Kg/ (Ht)2 in m 2 Waist Circumference Sagittal Abdominal Diameter Caliper-derived measurements of skin-fold thickness* Bioelectrical impedance analysis** Underwater weighing***
  8. INVESTIGATIONS
  9. INVESTIGATIONS
  10. INVESTIGATIONS
  11. INVESTIGATIONS
  12. INVESTIGATION Harpenden Professional Skinfold Caliper
  13. INVESTIGATION
  14. INVESTIGATION Ultrasonography Fat thickness Abd USS : NAFLD, Gallstones , Ovarian Cysts Dual-energy radiographic absorptiometry (DEXA) Abd CT Scan (at L4/L5) Abd MRI
  15. INVESTIGATIONs FLP LFT TFT FBG C-peptide and Insulin Studies Brain MRI* Genetic studies ** GH & IGF-1 Assays.
  16. TREATMENT GUIDELINES
  17. NON-PHARMACOLOGICAL MGT Diet, Physical Activity & Behavioural Therapy Self-monitoring of caloric intake & physical activity Goal setting* Stimulus control Non-food rewards Relapse prevention
  18. NON-PHARMACOLOGICAL MGT Goals should be SMART Who - Who is involved? What - What do I want to accomplish? Where - Identify a location When - Establish a time frame Which - Identify requirements and constraints Why - Identify specific reasons for or purpose or benefits of the goal
  19. NON-PHARMACOLOGICAL MGT Weight-loss programs 3 major phases : Pre-inclusion screening phase* Weight-loss phase Maintenance phase - Can last for rest of pt'slife but ideally lasts for at least 1 yr post program completion
  20. NON-PHARMACOLOGICAL MGT DIET Low Calorie Diet :800 - 1500 kcal/day Very Low Calorie Diet <800 kcal/day usu. high in protein (70 to 100 g/day) &low in fat (<15 g/day). Usu. Taken As Liquid Formula, Nutritional Bars Conventional Food : mostly lean meat, fish - known as protein-sparing modified fasts.
  21. NON-PHARMACOLOGICAL MGT Physical Activity More of Aerobic Isotonic Exercise* Less of Anaerobic Isometric/ Resistance Exercise**
  22. PHARMACOLOGICAL MGT Centrally acting medications that impair dietary intake (A) Medications that act peripherally to impair dietary absorption(B) Medications that increase energy expenditure (C)
  23. PHARMACOLOGICAL MGT Lipase Inhibitors : Orlistat (B) Sibutramine (C) Lorcaserin(A) Sympathomimetic Amines Phendimetrazine, Phentermine ,Diethylpropion, BenzphetamineMazindol(A) Antidiabetic agents
  24. PHARMACOLOGICAL MGT Of the drugs the following are FDA-approved: Lorcaserin (Belviq) Phentermine/topiramate (Qsymia) Orlistat (Xenical) Sibutramine no longer approved
  25. SURGICAL MGT BARIATIC SURGERY Roux-en-Y gastric bypass (M) Adjustable gastric banding (R) Gastric sleeve surgery (R) Vertical sleeve gastrectomy (R) Horizontal (Silastic ring) gastroplasty (R) Vertical banded gastroplasty (R) Duodenal-switch procedures(B) Biliopancreaticbypass (B) Biliopancreaticdiversion (B)
  26. SURGICAL MGT Morbid Obesity When Conventional Rx & Drug Rx Fail Benefits : Improved Obstructive sleep apnea Type 2 DM, Hypertension, CCF, Asthma, Dyslipidaemia Peripheral oedema, Respiratory insufficiency Esophagitis, Pseudotumorcerebri, OA, VTE Operative risk Urinary incontinence
  27. BENEFITS Improved Glycaemic Control BP Control Dyslipidaemia Control ↓ CV Risk Improved Pulm. Fx Improved Reproductive & Urinary Fx
  28. COMPLICATIONS OF Rx Electrolyte Disturbances : Ketosis, ↓K+ Arrhythmias Malabsorption Malnutrition Hyperuricaemia Cholithiasis Depression & Eating Disorders
  29. CONCLUSION Obesity is basically a clinical diagnosis More about body fat than weight Hx & PE very important to evaluate co-morbidities and Cx Management primarily non-pharmacological Multidisciplinary Benefits of Rx include ↓CV Risk, ↑Pulm. Fx and regression of co-morbidities
  30. REFERENCES Klein S, Fabbrini E, Romijnin JA Obesity in Melmed S, Polonsky KS, Larsen PR, Kronenberg HM (eds.), Williams Textbook of Endocrinology, 12th ed. Saunders, 2011. ch 36 pp 1605- 1625 Hamdy O, Citkowitz E, Uwaifo GI, Oral EA Obesity http://emedicine.medscape.com/article/123702. Updated : Nov 25, 2013 de Souza NC, de Oliveira EP Sagittal abdominal diameter shows better correlation with cardiovascular risk factors than waist circumference and BMI Journal of Diabetes & Metabolic Disorders 2013 12:41 http://www.topendsports.com/testing/skinfold-sites.htm Accessed Dec 4,2013 http://www.ebay.com/itm/Harpenden-Professional-Skinfold-Caliper-/320795435670 Accessed Dec 4, 2013
  31. REFERENCES http://www.fitnessgram.net/protocols/skinfolds.pdf Accessed Dec 6 ,2013 Sagittal Diameter http://www.myhealthywaist.org/evaluating-cmr/clinical-tools/sagittal-diameter/page/2/print.html. Accessed Dec 6, 2013 http://www.topendsports.com/testing/tests/underwater.htm Accessed Dec. 5,2013 http://www.topendsports.com/testing/siri-equation.htm Accessed Dec. 5, 2013 http://www.myhealthywaist.org/evaluating-cmr/clinical-tools/sagittal-diameter/page/2/print.html Accessed Dec. 6,2013 WHO Technical Report Series. Diet, nutrition and the prevention of chronic diseases http://whqlibdoc.who.int/trs/WHO_TRS_916.pdf Accessed Dec. 6, 2013
  32. THANK YOU
More Related